Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > ONCY's acquirer interested in breast, pancreatic, and GI CA

<< Previous

Bullboard Posts

Next >>

Post by Noteableon May 26, 2023 12:18pm

178 Views

Post# 35465924

ONCY's acquirer interested in breast, pancreatic, and GI CA

Big Pharma companies in Breast, Pancreatic and GI cancers would be seeking to use pelareorep in combination with immune checkpoint inhibitors, small molecules PARP and CDK 4/6 inhibitors, bispecifics and ADCs, and CAR-T therapy in solid tumors. Those are just a few reasons why Big Pharma companies are eagerly speaking with ONCY.

<< Previous

Bullboard Posts

Next >>

Who, why, and what of the great "Crypto Surge"